MLS on the verge of breaking above that 31p high of April 2002. This was the item that triggered the current breakout last week:

LONDON (AFX) - Medical Solutions PLC, the cancer and pathology services
group, said The Doctors Laboratory, the leading provider of private cervical
screening in the UK, has stated that they are adopting Medical Solutions'
SurePath for their LBC screening.
The SurePath system will be supplied by Medical Solutions in the UK under
licence from TriPath Imaging Inc.
Medical Solutions chief executive Charles Green said the group now awaits
the NICE (the National Institute of Clinical Excellence) report issuing their
final guidance to the NHS, after their preliminary report recommended the use of
liquid based cytology within the NHS. This report is expected in September.
newsdesk@afxnews.com
slm/

See impressive bb comment here since then and on various BBs.

Interims due mid-Sept.
Ahead of a long weekend there might yet be some profit-taking, but with results and statements to come within the next 2-3 weeks I would guess most who are planning to do so will reduce rather than exit, and the effect will be perhaps be outweighed by new buyers waking up to what's happening.

MLS don't have the field to themselves with the nhs - there are still other contenders in the running. But it's looking hopeful in my opinion.

Company website

External Shareholders at 21 Aug 03:
89.15m 2p Ords - Edinburgh Fund Mgrs PLC 6.32%, INVESCO Asset Mgmt Ltd 5.78%, Prudential PLC 5.61%, Cantor Fitzgerald Europe 5.34%, Texas Group PLC 4.12%, Singer & Friedlander Inv 3.45%, Other Dirs 1.65%.

jzl

Some mention in today's Daily Mail, I gather.

investtech.com automated analysis says re LMS:


Buy Candidate - Aug 22, 2003

Has risen 119% since the bottom on 30 Jan 2002 at 16.00. Has broken up through the ceiling of the rising trend channel, which signals an even stronger rising rate. The positive development, however, may give rise to short term corrections down from today's level. RSI is, however, overbought, which indicates a potential short-term reaction down. Positive volume balance, i.e. high volume in days of rising prices and low volume in days of falling prices, strengthens the stock in the short term. The stock has support at p 26.60.

(my thanks to SHB on another BB for this)

And now the Telegraph too has noticed MLS:

Medical Solutions

Medical Solutions is well placed to benefit from the National Institute for Clinical Excellence's decision to recommend a new type of testing for Britain's cervical screening programme.

This should increase demand for the MS SurePath technology. MS has successfully reinvented itself as focused pathology and cancer diagnosis business and is expected to move back into profit this year.

The shares have risen from 26p to 35p this week as investors warmed to the company's improved prognosis. But the shares have further to go. Buy for the longer term.

Juzzle, nice to see this on the move - I bought these back in 2000 @50p, watched them triple, sold half and still own the rest. They seem to have reinvented themselves of late and with interims due shortly + a positive news flow, things are looking good.

BTW another old "tech" period share I hold is SUN which is also on the rise (no pun intended) - nearly back to 50% of what I paid for them.

RNS Number:0738P
Medical Solutions PLC
27 August 2003

27 August 2003



Medical Solutions plc

Medical Solutions plc, the cancer and pathology services group, advises that its
interim results for the six months to 30 June 2003 will be announced on
Wednesday 17th September 2003.

An analyst briefing will be held in the Dome Room, No 1 Cornhill on the morning
of the announcement at 9.30am.

For further information please contact:

Ann-marie Wilkinson/Mike Wort, Beattie Financial 0207 398 3300

Resumption of the uptrend on news today.



RNS Number:2619P
Medical Solutions PLC
02 September 2003


Immediate Release 2 September 2003


MEDICAL SOLUTIONS plc

BOARD STRENGTHENED


Medical Solutions plc ("the Company" or "Medical"), the cancer and pathology
services group, today announces the following appointments to the Board. These
changes take immediate effect

Professor Karol Sikora (53), currently a Non-Executive Director of Medical, is
appointed to the Executive Board as Chief Scientific Director. Professor Sikora
joined Medical in April 2002, prior to which he held a number of senior research
positions within the pharmaceutical industry. These posts included: Vice
President of Global Clinical Research (Oncology) at Pharmacia Corporation;
Deputy Director of Clinical Research for the Imperial Cancer Research Fund;
Chief of the World Health Organisation and Clinical Director for Cancer Services
at Hammersmith Hospital, London.

Currently Professor Sikora is a Consultant to AstraZeneca; Special Adviser to
HCA Healthcare, the leading provider of healthcare services in America; Visiting
Professor of Cancer Medicine and honorary Consultant Oncologist at Imperial
College School of Medicine, Hammersmith Hospital, London.

Medical Solutions today also announces a second appointment - that of Dr Sue
Foden (50) who joins Medical as a Non-Executive Director. Dr Foden has
significant experience in the healthcare market having been Chief Executive of
Cancer Research Campaign Technology Limited (1987-2000) and Cancer Research
Ventures Limited (1998-2000).

Dr Foden is currently a Venture Partner of Merlin Biosciences Limited, the
specialist life science investor trust. As part of this role Dr Foden is a
Director of Ardana Bioscience Limited; BioVex Limited; De Novo Pharmaceuticals
Limited and PIramed Limited (all of whom Merlin Bioscience have an active
investment in).

Personally Dr Foden is a Director of the Institute of Cancer Research, Royal
Cancer Hospital, London; Cascade Fund Management Limited; NESTech Fund
Management Limited and Oxford Ancestors Limited, and is a member of the Wellcome
Trust's Technology Transfer Strategy Panel.

Commenting on the appointments, Charles Green, Chief Executive of Medical
Solutions said,

"We are delighted to announce these two appointments today, both of which add
significant weight to our management team. Professor Sikora has already proved
a great asset to the Board in his role as a Non-Executive and I am delighted
that he has decided to become a full-time member of the team.

I am also delighted that Dr Sue Foden has agreed to join Medical. She has
immense experience and knowledge in the biotechnology and pharmaceutical markets
and I very much look forward to working with Sue in driving Medical forward."


For further information, please contact:

Medical Solutions
Charles Green, Chief Executive Officer Tel: +44 (0) 115 973 9010
Andy Longstaffe, Finance Director

Beattie Financial Tel: +44 (0) 20 7398 3300
Mike Wort/ Ann-marie Wilkinson


Notes to Editors:

Medical Solutions plc provides world leading services and technology for cancer
diagnosis and pathology, supporting the Healthcare, Pharmaceutical and
Biotechnology sectors.

The group has two major divisions. The Services Division has a range of services
including Specialist Pathology, Biomaterials Resources and Expertise, and 5
Laboratories. These services are provided to the Pharma/Botech Industry
worldwide and to Healthcare providers, both public and private. The Technology
Divisions' range includes specialist imaging software for telemedicine, image
analysis and quantitation, and the SurePath liquid based cytology (smear test)
system. This division is also key in supporting its' Service divisions offerings
to both the Drug Development market and the Healthcare market.

The combination of world-renowned expertise, state of the art reference
laboratory facilities and innovative imaging technology puts Medical in a unique
position.


This information is provided by RNS
The company news service from the London Stock Exchange
END

LONDON (AFX) - Medical Solutions PLC, the supplier of services for drug
developers and healthcare providers, said it bought a second laboratory in
Dubai, the Histopathology & Specialty Laboratory (HSL), for 275,000 stg in
shares and cash.
A further 75,000 stg in cash is payable depending on the lab achieving
certain agreed financial targets.
In June Medical Solutions bought its first laboratory in Dubai, establishing
the company as a significant provider of speciality healthcare services in the
region.
The company said HSL will provide additional histopathology capacity
complementing its existing laboratory in Dubai.
newsdesk@afxnews.com
ak/

RNS Number:8475P
Medical Solutions PLC
17 September 2003

17 September 2003



MEDICAL SOLUTIONS

INTERIM RESULTS FOR THE PERIOD TO 30 JUNE 2003



Financial Highlights


* Turnover (on continuing operations) increases three fold to #2.9m
(2002: #1m)
* Profit after tax #0.5m (2002: #0.4m loss)
* Gross margin increased to 63% from 49%
* Continued investment in new services


Operational Highlights


* Consolidation of activities at Nottingham
* Widened services to support drug development - first contracts now in place
* NICE approval of Liquid Based Cytology (LBC) for Cervical Cancer Screening
in UK
* Acquisition of histopathology laboratory in London:
- Provides entry into private market
* Joint venture with Sonic for Cytology and LBC
* Acquisition of two private laboratories in Dubai, rapidly becoming a
centre of excellence for private healthcare services to the region
* Board strengthened with the appointment of Prof Karol Sikora to an
executive role on the board and the appointment of Dr Sue Foden as a non
executive director


Commenting the Chairman, Sir Gareth Roberts, said:

"Medical Solutions has transformed into a highly focused business specialising
in laboratory diagnosis and pathology for healthcare providers and support
services for drug developers. This has been a significant period of growth for
the company with turnover on continuing operations increasing threefold and the
completion of a number of key acquisitions.

We have a clear focus, and the necessary infrastructure and strategic alliances,
skills and technology to build a substantial and very profitable business."


For further information, please contact:
Medical Solutions
Charles Green, CEO Tel: +44 (0) 207 398 3300 (today only)
Andy Longstaffe, FD +44 (0) 115 973 9010


Beattie Financial
Mike Wort/Ann-marie Wilkinson Tel: +44 (0) 207 398 3300/07730 415019



Introduction

Medical Solutions has transformed into a highly focused business specialising in
laboratory diagnosis and pathology for healthcare providers and support services
for drug developers. During the first six months of 2003 we have taken several
key steps in achieving our vision of developing the new Nottingham facility into
an international centre of excellence. The combination of world-renowned
expertise, state of the art reference laboratory facilities and innovative image
analysis and quantitation technology puts Medical Solutions in a unique position
to fully exploit the increasing demand for outsourced support services.

The Group's business is divided into two main areas:

The Services Division delivers a range of services including specialist
pathology, biomaterials resources and expertise coupled with a number of its own
laboratory facilities. These services are provided to the global pharmaceutical
and biotechnology Industry as well as public and private healthcare providers.
Through creating new support services for drug development we are able to
develop new technologies and create a pipeline of products and services which we
can offer to our healthcare customers.

The Technology Division has a range of products, which includes specialist
software in telemedicine and imaging, and includes SurePath, our system for
preparing Liquid Based Cytology smear samples.

Operational Highlights

Key to the development and delivery of our range of services is the
consolidation of all activities at the new freehold premises on the new business
park in Nottingham. The building consists of 22,000sq metre of office and
laboratory space with room for expansion. The facilities will be fully
compliant with the requirements of IS9002, Clinical Pathology Accreditation
(CPA) and current Good Laboratory Practice (GLP) regulations. We have already
relocated our imaging businesses from Liverpool and Tunbridge Wells, and will be
moving our existing laboratories in Nottingham to the new site within the next 5
months.

During the period we have secured significant contracts with major
pharmaceutical companies and anticipate repeat orders of increasing magnitude as
they build up confidence in our capabilities. We have an expanding order book,
currently #2.3million, and order pipeline of some #4.5m with several individual
tenders valued over #1million.

In May we established an operation in Research Triangle Park(RTP), North
Carolina, USA, headed up by Dr Mark Browne, the founder of Kinetic Imaging to
meet the demand, centered around RTP, for expert analysis using our imaging
products to support drug discovery.

On 26 June 2003 we acquired a private laboratory in Dubai with annual post tax
profits of approximately #1million, and have established the company as a
provider and partner in Dubai Healthcare City (DHCC), the planned $2 billion
green-field development currently being constructed. The aim of the Dubai
Healthcare City initiative is to provide the highest quality healthcare services
through the creation of a world class cluster of healthcare professionals and
service providers to satisfy the needs of the expanding private hospital market
in Dubai, the Gulf, and its catchment area of 2 billion people in the region.
Other significant healthcare providers involved in the DHCC initiative include
The Harvard Medical School, The Johns Hopkins Medical Institute and The Mayo
Clinic. We are now well positioned to fulfil the laboratory needs, histopathogy
expertise and telepathology of this exciting new opportunity, in addition to
supporting its' public health systems.

On 14th August 2003 NICE (National Institute of Clinical Excellence) approved
Liquid Based Cytology for Cervical Cancer Screening in the UK. SurePath is one
of only two Food & Drug Agency approved Liquid Based Cytology smear test systems
which have been trialled by the NHS and reviewed by NICE, for implementation in
the UK. There are currently 4.7 million smear tests performed each year in
England and Wales. The continued delay of the announcement from the Department
of Health has caused great disappointment to the Company and this will impact
the full year performance. However, the Company believes that a full
contribution will come from SurePath in 2004.

On 4 July 2003 we acquired a private histopathology laboratory in London and
formed a joint venture with Sonic Healthcare, the listed Australian company, to
provide histopathology and cytology service in London and in the private
healthcare market outside London. This acquisition is also an important step in
creating the conduit through which we intend to offer LBC services to UK
healthcare providers.

Financial Overview

Turnover in this period from continuing operations trebled to #2.9 million (2002
#1.0 million), split as to #1.8 million (2002 #0.4million) from Services and
#1.1 million (2002 #0.6million) from Technology. Our order book is expanding
with contracts from a number of major pharmaceutical companies, and several
tenders worth in excess of #1million.

The Group's gross margin from continuing operations grew from 49% to 63%,
primarily due to the impact of the new business areas - reference laboratories,
drug development and private healthcare which attract significantly higher
margins than our historical business.

The operating loss from continuing operations was #1.07 million (2002 #1.08
million) including central costs. The gains in gross margin generated have been
offset by the investment in the expanded infrastructure built for our drug
development services in anticipation of the increased size of contracts and
order book.

Profit after tax for the period was #0.5 million (2002 #0.4million loss), helped
by the release of #1.5 million of the December 2002 provision for tax of #2.1
million, which related mainly to the disposal of Adams Healthcare.

At 30 June we had #4.4 million cash available. During the period we spent #4.3
million on capital expenditure including #3.7million on the freehold premises
in Nottingham, with the remainder on laboratory equipment. We acquired the
Welcare laboratory in Dubai for #7 million cash with #0.7million of costs. This
acquisition was partly financed by the issue of #2million worth of new ordinary
shares to the vendor with the remainder in cash. Deferred consideration of #3
million has been recognised in long-term creditors as we expect the laboratory
to exceed the warranted post tax profits of #0.95million for each of the first
three years under our ownership. During the period we also repaid the #2.4m
outstanding on Adams Healthcare debt, and assumed #4million of new debt. Cash
outflow from operations was #1.5 million in the period however #0.5 million
related to increased debtors as a result of sales made just prior to 30 June,
which have now been collected.

Board Changes

Dr Ian Ellis was appointed to the main Board as Medical Director in March. He
has been instrumental in the development of PathLore, our pathology diagnosis
business.

We were also delighted to appoint Professor Karol Sikora as Scientific Director,
who will have particular responsibility for leading our Drug Development
Services. Karol joined the group as a Non-Executive Director in April 2002. On
Karol's appointment as an Executive Director, we announced the appointment of Dr
Sue Foden as Non-Executive Director. Dr Foden has immense experience and
knowledge in the Biotechnology and Pharmaceutical markets having been Chief
Executive of Cancer Research Campaign Technology Limited (1987-2000) and Cancer
Research Ventures Limited (1998-2000). Dr Foden is currently a Venture Partner
of Merlin Biosciences Limited, the specialist life science investor trust.

Prospects

There remains a global shortage of pathologists, an increasing requirement for
specialist laboratories, a need for new technology and automation in pathology
and an expanding market for Private Healthcare. The support services we can now
offer in Drug Development represent a unique combination of services and
technologies which allows us to aid drug target identification, design and run
clinical trials, develop tests, and utilise those tests in expanding our service
offering for healthcare providers.

Our revenue streams are tangible and clear, and now include Dubai, the UK
private healthcare market, SurePath Liquid Based Cytology, and rapidly expanding
orders for our Drug Development services. We have the cash to finance the
business through to a cash generative position, and make positive additions to
our portfolio of skills and technologies.

We are now well positioned to deliver expectations in the forthcoming years as
the prospects of rapidly increasing our revenues are tangible. We have a clear
focus, and the necessary infrastructure and strategic alliances, skills and
technology to build a substantial and very profitable business.

Sir Gareth Roberts FRS, FREng
Non-Executive Chairman

Looking intersting again over the last couple of days - a break above 39 would be nice.

Cleared the busy area around 39p yesterday and a small tick up today - still long and chart shows much fresh air above this level.

what other update news from MLS?

Sold half my holding this morning for +50% which was nice.

RNS Number:1624R
Medical Solutions PLC
22 October 2003





October 22, 2003



Medical Solutions announces Department of Health decision on

Liquid Based Cytology





Medical Solutions (LSE: MLS), the cancer diagnostics company, announces that the
Department of Health has today accepted the decision by NICE that a new cervical
screening system - Liquid Based Cytology ("LBC") will replace the current
cervical smear test in England and Wales.



Medical Solutions will supply its SurePath LBC system, which has been used for
the NICE (National Institute of Clinical Excellence) pilot study. The
excellent results the SurePath LBC System obtained in the NICE pilot for both
cancer detection and reduction in inadequate tests has greatly contributed to
the decision by DOH to adopt the NICE guidance on LBC in England and Wales.



The SurePath LBC system is more effective than conventional smear tests in
picking up likely cancer cases and US studies have demonstrated a 64.4%
improvement over conventional methods in the detection of high grade
abnormalities. The system introduced by SurePath is automated thereby reducing
any operator errors and increasing the efficiency of the new LBC test. Early
detection of such abnormalities greatly increases the chances of effective
treatment.



LBC is also a significant step towards the introduction of even more powerful
detection tools in the future including automatic imaging and molecular markers.
The SurePath LBC system already has some of these systems approved in the US and
trials are underway in the UK.



Charles Green CEO of Medical Solutions said



"We are delighted by the Department of Health's adoption of LBC in England and
Wales. The Medical Solutions Surepath LBC system is one of only two FDA
approved products and our unique technologies will ensure greatly improved
collection and screening of the four million smears performed every year."



Contact:



Medical Solutions
Charles Green, Chief Executive Officer Tel: +44 (0) 115 973 9010

anymoe good news? look like this share worth to hold from now on....

GREAT NEWS FOR YOU/SHAREHOLDERS
Up 8.50 / 17.99 per cent @ 4,736,092 million volume
I forget the www I found it.
................................
More info:
www.moneyextra.com/stocks/LSE/MLS---------Click company news.

Plenty of favourable press coverage this weekend so far. Some profit-taking was to be expected yesterday at the end of such a positive week, but the share price soaked up those sells with ease.

Analysts and brokers newly alerted to this stock by the nhs and related government statement should be coming up with upgrades soon. Plus the possibility of it becoming a very tasty takeover target now that it looks like taking a fair chunk of that nhs business. Not that it is reliant on the LBC cervical cancer testing work. It has several solid divisions (expect some newsflow from those between now and end of year).

Sonic (Australian Top-100 company) has an active connection with MLS on several fronts and is considered by many to be a likely bidder at some stage.

jzl

Some more on Sonic - lifted from an excellent piece by S-H-B on another BB:

..Sonic is the largest medical diagnostics Company in Australasia and New Zealand, providing quality Pathology and radiology services in the community.

...has made rapid progress and turnover is now almost 1billion AUS dollars.

Sonic Stategy:
Capture synergies with Sonic pathology
Build relationships with independent healthcare entities
Acquisitions
UK pathology opportunities
European pathology

Sonic Statement:
The group’s UK operation, TDL, continues to perform strongly, with significant growth in both revenue and EBITA. Recent developments in the UK include the acquisition of the Omnilabs pathology group in July 2003 and the announcement of a strategic joint venture with the University College London Hospital (UCLH), one of the UK’s most prestigious teaching hospitals. TDL (including the merged Omnilabs operation), is expected to move into a new, state-of-the-art laboratory facility in December 2003 and will partner with UCLH to form a high-volume automated laboratory in the new facility for the routine pathology testing of both entities.

Dr Goldschmidt said that the UCLH joint venture represented an important milestone in Sonic’s history. “We are privileged to work with UCLH and we anticipate that the relationship will bring benefits to both groups at many levels. The TDL/UCLH joint venture will create the platform for growth in both the public and private pathology markets in the UK"


As above, Sonic are very very keen to gain a major foothold in the NHS, and be part of the NHS Pathology modernisation plan this has been achieved with having contracts with the NHS through TDL, and now having very close ties with MLS who are firmly established throughout the NHS, this puts Sonic now in the position as a 'stalking horse' waiting for the opportune moment to make their move on MLS.

Karol Sikora is an advisor for Astra Zeneca and does work for HCA a large US Healthcare company, But Sonic are purely a diagnostics company who have a foothold in the UK market and with Medicals business operations would be an ideal synergistic fit for Sonic.

Detailed info about Sonic and Company stategies can be found on this link
http://www.sonichealthcare.com/sonic/internet/html_corporate/index.html

2004 saw Medical Solution go from Greatness to Weakness, yet here there are no comments - - -

This stock has got to be a one way bet, it'll go back up as fast as it fell as soon as some news is out. Any thoughts on this one's future

20 times as many buys as sells today, and previous days. Something big is coming soon

snaylor

Clearly, the placing has gone well. My information is that the new board members have been well received. The city has clearly backed them in seeing off the hostile bid. Thus it is seen that the company should recover. I doubt whether there has been time for any trading improvement. Rather, the fall was overdone.

Eric

Fascinated at the lack of comment on this bb. Positive news out to day with Surepath sales. Successful fundraising behind them. Strong new board members on board. Focussing on getting the finances in order. What is more: Evil Knievel has a LONG position in MLS. Anyone with inside view of the market?

Eric

Another post to repeat the question of the last one to keep it on top page. I will go on doing this until I get an answer! Can anyone tell me what this company is worth?

Eric

Not me;- but I did buy-in a lot higher in the days when they were about to gain NHS money, which I understand has been their downfall.
/
When a co really disapoints it takes a lot of positive news (over a sustained time) to convince folk that the company is worthwhile. I haven't subscribed recently as it was too close to the market price IMHO. The drift down more-or-less confirms this. Maybe a new strategy is in order, but the sp will not react until it shows some results.
Keep asking the questions, EWRobson - someone must know.

Thanks, hangon. I think you are right re the need for sustained good news. There are many AIM companies way down from their best and below placing prices. There doesn't appear to be much hot money there for breaking positive stories either. You keep wondering whether companies like MLS, YOO and CYH can drift lower and they do, because of lack of buyers.

Would also appreciate others views on this stock and think you are both correct re the need for continual good news.

From my understanding MLS is not an Aim stock.

Thanks for trying to keep this on the top page.

Sorry, the same old chap and not another! Just been looking at the Hemscott figures and the updated broker forecasts. Charles Stanley, house broker, have reduced from Buy to Hold. What is more, or less, they are not forecasting profits in the next two financial years. So I doubt if tis a buy this time of the summer recess - there's so much more positive around which is not moving. Hold might be OK because price might just bobble along the bottom for a while.

Eric

8 June 2006

Medical Solutions plc

("Medical Solutions" or "the Group")

Annual General Meeting

Sir Gareth Roberts, Chairman of Medical Solutions plc will be making the
following statement at the 2006 Annual General Meeting today:

"Following the significant improvement in the Group's financial and operating
performance during 2005, I am pleased to report that excellent progress has
been made during the early part of 2006.

Trading update

We stated in our 2005 Annual Report that we had targeted sales growth rates of
around 20-25% for the year ending 31 December 2006 and I am delighted to report
that, over the early part of the year, this is a target that we have exceeded.
Our operating costs remain under control and our cash position has been well
managed.

This is good news for the future, probaly why someone bought significant 1m recently.

A good post from AFN, which may be linked to EK and talk about Cancer treatments etc.. that might be throwing lots of lots of money the way of MLS..


Rex Taurus - 9 Jun'06 - 09:47


From yesterday's AGM statement:


In the UK Diagnostic Pathology business, progress during the early part of the
year has been excellent following the continued high demand experienced for our
service offerings, including the Her 2 test, designed to establish whether or
not a patient suffering with breast cancer will respond to the drug
HerceptinTM.



Today's News:

http://icwales.icnetwork.co.uk/0100news/0200wales/tm_objectid=17201787&method=full&siteid=50082&headline=-thousands-of-lives-saved--as-herceptin-approved-for-nhs-name_page.html

'Thousands of lives saved' as Herceptin approved

Notice of Results

RNS Number:1211I
Medical Solutions PLC
25 August 2006


Medical Solutions plc

Notice of Interim Results

Medical Solutions plc, the provider of pathology and cytology products and
services to the healthcare and pharmaceuticals sector, will announce interim
results for the six months ended 30 June 2006 on Thursday 31 August 2006.

-Ends-

For further information:

Medical Solutions
Neil Johnston 0115 973 9010

Bell Pottinger
Geoff Callow/Chris Hamilton 020 7861 3232




This information is provided by RNS
The company news service from the London Stock Exchange

Heck, did I really start this thread??
It was OK for about 2 months from then :-o

And I was so much younger and innocent..

Great set of results, reports maiden profit....

Interim Results

RNS Number:2764I
Medical Solutions PLC
31 August 2006



For further information, please contact:
Medical Solutions plc
Neil Johnston
Tel: 0115 973 9010
www.medical-solutions.co.uk

Bell Pottinger Corporate & Financial
Geoff Callow/Chris Hamilton
Tel: 0207 861 3232



Medical Solutions plc

Interim results for the six months ended 30 June 2006


Medical Solutions plc (LSE: MLS), the provider of pathology and cytology
services and products to the healthcare and pharmaceuticals sectors, announces
its unaudited interim results for the six months ended 30 June 2006.


Financial Highlights

* Turnover from continuing operations up 36% to #6.8 million (H1 2005:
#5.0 million)

* Achievement of maiden operating profits of #66,000 (H1 2005: operating
loss of #1.0 million)

* Cash generative during period; net cash of #2.7 million at 30 June 2006
(31 December 2005: #2.3 million)

* Net profit for the period of #26,000 (H1 2005: net loss of #1.1 million)

Operational Highlights


* Advanced discussions in progress regarding the proposed sale of the
Group's Dubai business

* Liquid Based Cytology ("LBC") exclusive distribution agreement with
Tripath Imaging, Inc. renewed until 31 December 2010

* LBC 45% target market share (England and Wales) now achieved; further
contracts yet to be awarded

* New products launched in UK Diagnostic Pathology and Drug Development
Services divisions

* Currently supporting key UK trials designed to evaluate automated
cervical smear screening, a major potential growth market

Board changes

* Charles Green steps down as Chief Executive Officer with immediate
effect; Neil Johnston appointed as Chief Executive Officer, Nick Ash appointed
as Chief Financial Officer

Sir Gareth Roberts, Chairman, said:

"We have made an excellent start to the year and have achieved a profitable,
cash generative position for the first time. Discussions regarding the proposed
sale of the Dubai business have also been positive and we expect to be able to
make a further announcement on this subject in the near future.

As part of a planned succession, Charles Green will be stepping down as Chief
Executive Officer and Neil Johnston has been appointed as his successor, both
with immediate effect. Dr Nick Ash, previously Group Financial Controller, has
been appointed to the Board of Directors as Chief Financial Officer. On behalf
of the Board, I would like to express our thanks to Charles for all his efforts
during his time with Medical Solutions plc and wish him well in the future."

Chairman's Statement

Introduction

During the first half of 2006, we have continued to focus on our key short term
objectives, namely profitability and cash generation. I am delighted to report
that both objectives have been achieved for the six months ended 30 June 2006.

Financial and Operational Review

Financial Review

Turnover for the six months ended 30 June 2006 increased by 36% to #6.8 million
compared with #5.0 million in the first half of 2005. This is our third
successive period in which we have demonstrated strong revenue growth. The
increase in turnover during the period has been driven primarily by growth in
our Cytology division and in Dubai with revenues having increased by 90% and 55%
respectively.

Gross margins have improved from #1.9 million (39%) for the first six months of
2005 to #2.8 million (41%) as a result of further improvements in the efficiency
of our operations during the period.

Operating expenses (excluding exceptional restructuring costs and gains on sales
of fixed assets) have decreased to #2.7 million for the six months ended 30 June
2006 from #3.1 million during the same period in 2005. Operating expenses for
the period also include a charge of #0.1 million relating to a share option
based compensation charge as required by IFRS 2 (H1 2005: #0.1 million). These
savings have been achieved through a combination of further efforts to improve
the efficiency of our operations and the ongoing effects of decisions taken
during 2005, such as the closure of the Harley Street facility. No taxation
charge has been recognised in the period (H1 2005: #nil) as the profits of the
Dubai operations are not subject to taxation locally and the Group has tax
losses available to offset profits in the UK.

Net cash inflow from operating activities during the six months ended 30 June
2006 was #0.8 million (H1 2005: cash outflow of #1.8 million). Capital
expenditure of #0.2 million was incurred during the period (H1 2005: #0.2
million) in connection with LBC machines and laboratory equipment in the UK and
Dubai and we have repaid borrowings (including minority interests) of #0.2
million. The Group had a net cash balance of #2.7 million as at 30 June 2006 (31
December 2005: #2.3 million).

Operational Review

Pathology Services

UK Diagnostic Pathology ("UKDP")

Overall sales in H1 2006 have been consistent with those achieved in H1 2005 at
#1.3 million. This masks the underlying improvement in this area of our
business. We have seen higher volumes of specialist testing through our
Reference Laboratory during the period, which has offset 2005 revenues in the
Virtual Microscopy area (#0.2 million), which we have since exited.

We have continued to demonstrate improvements in the profitability of this part
of our business. UKDP generated an operating profit of #337,000 during the
period (a 26% return on sales) compared with #102,000 in H1 2005, the latter
including a #387,000 one-off profit on the sale of certain intellectual property
rights.

During the second half of 2006 we are looking to develop this area of our
business through investment in new specialist testing services in the cancer
area and an increase in the size of our UK business development team.


Over the next few years, we see major opportunities to grow our UKDP business
through partnerships with the NHS. The recent review of NHS Pathology Services
by Lord Carter of Coles was clear in envisaging the potential for significant
benefit from further involvement of the independent sector in the provision of
pathology services in England.

Dubai Diagnostic Pathology

Our business in Dubai has continued to perform strongly. Sales are up by 55% to
#3.6 million from #2.3 million primarily due to the continued positive impact of
the Labour Medical Testing programme being conducted by Specialised Clinical
Laboratory ("SCL") in conjunction with the UAE Government. Operating profits
have improved from #0.7 million in H1 2005 to #1.3 million in H1 2006.

In March 2006, we announced that we had reached agreement with representatives
of the Varkey Group and Welcare Hospital to settle the outstanding #2.5 million
contingent deferred consideration, recognised as a provision in the consolidated
balance sheet, relating to the acquisition of the Welcare Laboratory in 2003 and
to recover the #0.9 million owed to Medical Solutions by Welcare Hospital. In
May 2006, we announced that we believed that this transaction would be completed
as part of a sale of the whole of the Group's interests in Dubai.

Drug Development Services ("DDS")

Sales in our DDS business have been disappointing mainly as a result of a
reduced level of business from AstraZeneca compared with the same period in
2005. We reduced our annual direct costs significantly during 2005 and our
annual cash investment during 2006 is expected to be around #0.6 to #0.7 million
bringing a cash breakeven result within reach.

We have introduced a new service offering based on Circulating Tumour Cell
("CTC") technology in May and announced our first contract with an undisclosed
major pharmaceutical company. We are hopeful of further contracts in this area.

On the basis of a relatively low ongoing investment in DDS and our belief that
this customer base will be an important part of our growth as our business
develops, it is our current intention to retain this part of our business.

Cytology

The Cytology division has performed strongly during the six months ended 30 June
2006. Sales have increased to #1.7 million from #0.9 million, a 90% increase.
Operating profits have improved to #262,000 in H1 2006 from a small loss of
#26,000 during H1 2005. During the period we have announced an agreement with
the Hereford and Telford Processing and Screening Laboratories Network. We have
also begun to supply two other regions in the Midlands area. As a result of
these business gains, we have achieved our targeted LBC market share in England
and Wales of 45%. We expect further contract wins in this part of our business.

We have also signed a further extension to our exclusive LBC distribution
agreement for the UK and Ireland with Tripath Imaging, Inc. ("Tripath"),
extending the original agreement until 31 December 2010.

In partnership with Tripath, we are currently supporting two UK based trials
designed to evaluate an automated approach to cervical screening. This
technology is already being used successfully in other European countries and
has the potential to revolutionise the efficiency of the current screening
process. This is of particular importance in the UK at present given the severe
pressures faced by laboratories in achieving adequate staffing levels resulting
in lengthy turnaround times for results. We are particularly excited about the
future of automated screening and are reviewing alternative business models
through which we can maximise shareholder value.

Update on planned sale of Dubai Diagnostic Pathology

We previously announced our decision to exit from our business in Dubai in order
to focus on and invest in, our UK operation and maximise its potential. Since we
last reported, we have continued discussions with a number of different parties
who have expressed interest in our Dubai operation. We are currently in advanced
discussions with our preferred purchaser and expect to make a further
announcement on this subject in the near future.

Board Changes

With immediate effect, Mr Charles Green will step down as Chief Executive
Officer. As part of the planned succession, Dr Neil Johnston has been appointed
as Chief Executive Officer and Dr Nick Ash, who joined the Group during 2005 as
Group Financial Controller, will become Chief Financial Officer. Mr Green will
remain with the Dubai business on a consultancy basis for an interim period.

Prospects

During the six months ended 30 June 2006, we have made further progress and have
achieved our immediate targets of profitability and cash generation. We are not
complacent about the challenges that lie ahead but we look forward to the future
with renewed optimism based upon the continued improvement in our financial
performance and the significant market opportunities which await.

Sir Gareth Roberts
Chairman
31 August 2006

Rodders

LONDON (AFX) - Medical Solutions PLC made a maiden profit in the first half to June 30 2006 of 26,000 stg before tax, up from a loss of 1.1 mln in 2005.

The group, which provides pathology and cytology services and products to the healthcare and pharmaceuticals sectors, also announced today that Charles Green has stepped down as chief executive officer and resigned from the board. Green will remain with the company's Dubai business, which is currently up for sale, on a consultancy basis for an interim period.

As part of the planned succession, Dr Neil Johnston has been appointed as chief executive officer from his previous position of chief financial officer and company secretary. Johnston will in turn be succeded by Dr Nick Ash.

In the period under review, the group said its turnover from continuing operations was up 36 pct to 6.8 mln stg.

The board also said it is in advanced discussions regarding the proposed sale of the group's Dubai business.

newsdesk@afxnews.com slm

I bought shares in MLS on Wednesday 30th of this month.

I thought it strange that it never showed. Not the norm is it.

Listed on another exchange try this.....

http://www.plusmarketsgroup.com/details.shtml?ISIN=GB0009739649

Rodders

rodspotty

Thank You.

Disposal

RNS Number:3321J
Medical Solutions PLC
22 September 2006




Medical Solutions plc
(the "Company" or "Medical Solutions")

Proposed disposal of the Dubai based business of the Company

Medical Solutions, the provider of pathology and cytology services and products
to the healthcare and pharmaceuticals sectors, today announces that it has
entered into conditional agreements to sell 100% of the issued share capital in
Medical Solutions FZ LLC ("Dubai MedSol") its Dubai based pathology business for
an anticipated gross consideration of #16.4 million before expenses.

Summary of the transaction

*83.4% of the issued share capital in Dubai MedSol will be sold to
two Middle Eastern investment entities, Global Fund Company (Bahrain) EC and
Global Investment House KSCC based in Kuwait, for a consideration of #12.9
million payable in cash.

*The Consideration is also subject to adjustments in respect of cash
and working capital balances in Dubai MedSol as at 31 August 2006 which is
expected to result in an additional payment of #1.0 million to the Company.

*The remaining 16.6% of the issued share capital in Dubai MedSol will
be transferred to International Healthcare Holdings Limited ("IHHL"), a company
controlled by Mr Sunny Varkey in full and final settlement of a debt of #2.5
million owing by Medical Solutions plc to Welcare Hospital LLC and Welcare World
Health Systems Limited, both companies controlled by Mr Sunny Varkey.

*Cash consideration is therefore expected to be approximately #13.9
million before deduction of estimated expenses of approximately #1.0 million.

*The Directors intend to use the expected net cash proceeds of #12.9
million to invest in the Company's UK pathology and cytology businesses. The
Directors also intend to conduct a full strategic review before the end of the
year.

Neil Johnston, Chief Executive of Medical Solutions plc said,

"In December 2004 the Board outlined a clear strategy for the future development
of Medical Solutions that would set the company on the path to profitability.
The initial benefits of this strategy were highlighted by the Group announcing a
maiden profit in its interim results for the six months ended 30 June 2006. The
sale of the Dubai businesses is the latest stage in the process of ensuring the
long term success of the Company and the funds generated will enable significant
investment in the UK pathology and cytology businesses that will form the main
focus of operations going forward."

Enquiries:
Medical Solutions plc
Neil Johnston, Chief Executive Officer 0115 973 9010
Nick Ash, Chief Financial Officer 0115 973 9010

Bell Pottinger Corporate & Financial
Geoff Callow/Chris Hamilton 020 7861 3232

Nomura Code Securities Limited
Richard Potts 020 7776 1200

Details of the proposed sale of Dubai MedSol

This is NOT a ramp, but to demonstrate just how depressed the medical sector is, MLS will soon have 15m in cash, when the Dubai disposal is complete(see todays ''A''), the market cap at the present share price is 12.5m, which values their UK diagnostics business at sub zero ????? DYOR

Rodders

From FT.com

Medical Solutions rose 6.4 per cent to 6.1p after announcing the sale of its Dubai labs business for 12.9m, or 500,000 more than its curernt market value. The company will use the proceeds to invest in its UK pathology and cytology business, which Nomura Code Securities reckons is worth 12m.

Rodders

MLS on the rise this morning, little or no trades, still trading at a discount to cash with the business thrown in for free (valued by Nomura in a recent BUY note at 12m). DYOR

Rodders

From FT today

Here is the link.

http://www.ft.com/cms/s/92381f54-54d6-11db-901f-0000779e2340.html

"SMALL-CAPS: MBO TALK LIFTS MEDICAL SOLUTIONS
By Robert Orr and Neil Hume

Published: October 6 2006 03:00 | Last updated: October 6 2006 03:00

*Talk of a management buy-out approach sent Medical Solutions 12.5 per cent higher to 6p. Shares in the healthcare technology group have failed to break through 10p for the best part of two years. It recently sold its Dubai pathology business for 12.9m, roughly equal to its present market value."


Rodders

On the up today and well bid, EVO's seem keen. DYOR

Rodders

On the up again today, with EVO's again aggresively on the bid, share price still below cash in the bank. EGM tomorrow to rubber stamp the sale of their Dubai opps. DYOR

Rodders